Top ▲

Follicular lymphoma

Disease ID:1228
Name:Follicular lymphoma
Associated with:0 target
1 immuno-relevant ligand
An indolent non-Hodgkin lymphoma.
Database Links
Disease Ontology: DOID:0050873


No target related data available for Follicular lymphoma


Key to terms and symbols Click ligand name to view ligand summary Click column headers to sort
Ligand References Clinical and Disease comments
Immuno Disease Comments: Approval is for a combination therapy of obinutuzumab with bendamustine, followed by obinutuzumab monotherapy.
Clinical Use: Initially approved to treat chronic lymphocytic leukemia (CLL) in combination with chemotherapy in patients who have received no prior therapy. In November 2012, this antibody was authorised as an orphan drug by the EMA for the treatment of CLL. Full EMA approval for CLL was granted in July 2014.
In February 2016, the US FDA expanded approval to include treatment of patients with follicular lymphoma (FL) who have relapsed after, or are refractory to, a -containing regimen. This new approval is for a combination therapy of obinutuzumab with , followed by obinutuzumab monotherapy. | View clinical data
Bioactivity Comments: In vitro, obinutuzumab induces cell death and antibody-dependent cell-mediated cytotoxicity (ADCC) more effectively than the original type I anti-CD20 antibodies and [1]. In vivo, obinutuzumab induces a strong antitumour effect [1].
However, we have been unable to find affinity data for this antibody from any open access source. | View biological activity


Show »

1. Herter S, Herting F, Mundigl O, Waldhauer I, Weinzierl T, Fauti T, Muth G, Ziegler-Landesberger D, Van Puijenbroek E, Lang S et al.. (2013) Preclinical activity of the type II CD20 antibody GA101 (obinutuzumab) compared with rituximab and ofatumumab in vitro and in xenograft models. Mol. Cancer Ther., 12 (10): 2031-42. [PMID:23873847]